SUBSCRIBE
SUBSCRIBE

Brandon May

Pavlo Gonchar/SOPA Images/LightRocket via Getty Im
Drug Development
After Months of Prodding, CDC Updates Guidance on COVID-19 Airborne Transmission
The CDC says that COVID-19 is an airborne threat, stating that transmission and subsequent infection can occur via inhalation of very fine respiratory droplets and aerosolized particles.
May 10, 2021
 · 
3 min read
 · 
Brandon May
Business
Nkarta and CRISPR Therapeutics Join Forces to Develop Natural Killer Cell Cancer Treatments
Biopharmaceutical company CRISPR Therapeutics has entered into a strategic research, development and commercialization partnership with cancer-focused Nkarta.
May 7, 2021
 · 
3 min read
 · 
Brandon May
Onivyde failed in the trial of late-stage small ce
Drug Development
AstraZeneca’s Tremelimumab Offers Survival Benefit With IMFINZI in Advanced Lung Cancer
A final analysis of AstraZeneca’s Phase III POSEIDON trial shows IMFINZI (durvalumab), offered improvements in overall survival (OS) when added to tremelimumab and chemotherapy versus chemotherapy alone in patients with Stage IV (metastatic) non-small cell lung cancer.
May 7, 2021
 · 
2 min read
 · 
Brandon May
Deals
Two Companies Growing via Acquisitions this Week
Two new notable biotech/biopharma acquisitions were reported this week: Athenex has acquired Kuur Therapeutics, while Altasciences has acquired preclinical CRO Calvert Laboratories.
May 6, 2021
 · 
2 min read
 · 
Brandon May
Vaccine
BioCapital
Current COVID-19 Vaccines Proving Efficacy Against New Variants
Newly-published studies suggest currently authorized COVID-19 vaccines may be effective for protecting against new and emerging variants of the novel coronavirus, while booster doses of these vaccines may improve the overall efficiencies of these immunizations at combating these variants.
May 6, 2021
 · 
4 min read
 · 
Brandon May
Drug Development
COVID-19 May Increase Risk of Diabetes, New Study Claims
Patients without diabetes who develop COVID-19 may be at a higher risk of actually developing diabetes following recovery, recent study claims.
May 5, 2021
 · 
2 min read
 · 
Brandon May
Sarah Silbiger/Getty Images
Drug Development
FDA Cites Concerns Over ChemoCentryx’s Avacopan Trial Data, Sending Stock off a Cliff
The U.S. FDA cites concerns regarding clinical data for ChemoCentryx’s investigational rare autoimmune disease therapy avacopan. Shares in the company plunged 46.5% lower following the release of the document.
May 5, 2021
 · 
3 min read
 · 
Brandon May
Business
Changing of the Guard: Four Biopharma Companies Appoint New CEOs
Companies across the biotech and biopharma industries recently reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.
May 4, 2021
 · 
3 min read
 · 
Brandon May
Pictured: Sarepta sign on a brick building/courtes
Drug Development
Sarepta’s Second Muscular Dystrophy Drug Shows Greater Promise in Phase II
Sarepta Therapeutics announced Monday that its next-generation PPMO candidate, SRP-5051, showed promise in a Phase II trial when used as a treatment for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
May 4, 2021
 · 
2 min read
 · 
Brandon May
Business
Relay Therapeutics Appoints Key Leadership Members Following Acquisition
Clinical-stage precision medicine company Relay Therapeutics has brought two new senior level management team members into the fold, including Tara O’Meara and Charles Ferté.
May 3, 2021
 · 
3 min read
 · 
Brandon May
Six Dementia Patients Received Controversial Gene Therapy Injection in Mexico, BioVia Says
If actually administered to these patients, this could represent the first recorded attempt to manage dementia that uses an injectable gene therapy technique.
May 3, 2021
 · 
3 min read
 · 
Brandon May
Policy
Bristol Myers’ Opdivo Fails to Maintain Accelerated Approval in Liver Cancer
The U.S. FDA’s Oncologic Drugs Advisory Committee did not agree in a recent meeting to maintain the accelerated approval of Bristol Myers Squibb’s Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma.
April 30, 2021
 · 
3 min read
 · 
Brandon May
Drug Development
Tetra’s Alzheimer’s Drug Improves Language, Learning in Fragile X Syndrome
An investigational Alzheimer’s disease drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.
April 30, 2021
 · 
2 min read
 · 
Brandon May
Biogen is planning to cut its Alzheimer's drug Adu
FDA
FDA Blocks Biogen’s sBLA for MS Drug
The U.S. FDA says it is unable to approve Biogen supplemental Biologic License Application (sBLA) for subcutaneously delivered TYSABRI® for the treatment of relapsing multiple sclerosis (MS), at least while the sBLA remains in its present form.
April 29, 2021
 · 
2 min read
 · 
Brandon May
Sarah Silbiger/Getty Images
FDA
Acceleron Finds Itself in FDA’s Crosshairs After Failure to Post Clinical Data Summary
The FDA is threatening Acceleron with a $10,000 fine or criminal prosecution, charging the company with failure to post a summary of study data on its cancer combo dalantercept and axitinib in the ClinicalTrials.gov online database.
April 29, 2021
 · 
2 min read
 · 
Brandon May
Load More